119 related articles for article (PubMed ID: 17004081)
1. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
Dengler I; Leukel N; Meuser T; Jost WH
Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
[TBL] [Abstract][Full Text] [Related]
2. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
4. Costs of drug treatment in Parkinson's disease.
Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
[TBL] [Abstract][Full Text] [Related]
6. Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
[TBL] [Abstract][Full Text] [Related]
7. [Parkinson's disease: cost-of-illness in an outpatient cohort].
Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of direct costs in therapy of Parkinson disease].
Keller S; Kessler T; Meuser T; Fogel W; Bremen D; Jost WH
Nervenarzt; 2003 Dec; 74(12):1105-9. PubMed ID: 14647911
[TBL] [Abstract][Full Text] [Related]
9. Direct costs of managing Parkinson's disease in India: concerns in a developing country.
Ragothaman M; Govindappa ST; Rattihalli R; Subbakrishna DK; Muthane UB
Mov Disord; 2006 Oct; 21(10):1755-8. PubMed ID: 16874759
[TBL] [Abstract][Full Text] [Related]
10. [Indirect costs in idiopathic Parkinson's disease].
Barth F; Baum B; Bremen D; Meuser T; Jost WH
Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
[TBL] [Abstract][Full Text] [Related]
11. [Cost of care for depressive disorders in primary and specialized care in Germany].
Salize HJ; Stamm K; Schubert M; Bergmann F; Härter M; Berger M; Gaebel W; Schneider F
Psychiatr Prax; 2004 Apr; 31(3):147-56. PubMed ID: 15042478
[TBL] [Abstract][Full Text] [Related]
12. Drug costs for patients with Parkinson's disease in two different European countries.
Vossius C; Gjerstad M; Baas H; Larsen JP
Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
[TBL] [Abstract][Full Text] [Related]
14. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
[TBL] [Abstract][Full Text] [Related]
15. [Health insurance expenses for children in the first five years of life - a cohort-based analysis].
Reichert J; Schemken M; Manthei R; Steinbronn R; Bucher U; Albrecht M; Rüdiger M
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):451-60. PubMed ID: 24238022
[TBL] [Abstract][Full Text] [Related]
16. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
[TBL] [Abstract][Full Text] [Related]
17. [Costs and benefits of an education program for patients with ankylosing spondylitis as part of an inpatient rehabilitation programs-study design and first results].
Krauth C; Rieger J; Bönisch A; Ehlebracht-König I
Z Rheumatol; 2003; 62(Suppl 2):II14-6. PubMed ID: 14648082
[TBL] [Abstract][Full Text] [Related]
18. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
19. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
[TBL] [Abstract][Full Text] [Related]
20. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
